BillionToOne公司推出的超灵敏液体活检技术，正在日本市场显著提升耐药性非小细胞肺癌患者获得精准医疗的机会。这项创新检测方法通过高灵敏度分析血液中的循环肿瘤DNA，能够精准识别对传统治疗方案产生抵抗的肺癌患者的特定基因突变，从而为临床医生制定个性化治疗策略提供关键依据。
目前，该技术已开始在日本多家医疗机构推广应用，有望改变耐药非小细胞肺癌患者的治疗格局。与传统组织活检相比，液体活检具有创伤小、可重复性强等优势，特别适合需要长期监测治疗反应的患者群体。随着精准医疗理念的深入，这项技术将为更多日本肺癌患者带来新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.